|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
|
17961073 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
With respect to prostate cancer, prostatic acid phosphatase, prostate‑specific antigen, prostate‑specific membrane antigen (PSMA), prostate stem cell antigen, T‑cell receptor γ alternate reading frame protein, transient receptor potential‑p8 and six‑transmembrane epithelial antigen of the prostate 1 are among the identified target antigens for prostate tumors.
|
30542701 |
2018 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we characterize a second candidate tissue biomarker, hCAP-D3, expressed in subtype-1 prostate tumors. hCAP-D3 expression, assayed by RNA in situ hybridization on a tissue microarray comprising 225 cases, was associated with decreased tumor recurrence after radical prostatectomy (P=0.004), independent of pathologic tumor stage, Gleason grade, and preoperative prostate-specific antigen levels.
|
18223322 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the lower expression levels of CCND2 markedly correlated with prostate tumor progression to high Gleason score and elevated PSA levels, and served as an independent predictor of biochemical relapse and overall survival in a large cohort of prostate cancer patients.
|
28674394 |
2017 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
|
19116992 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrated that the 620-dp DNA fragment actively drives gene expression in LNCaP, a PSA-producing prostate tumor cell line.
|
8573614 |
1995 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
|
16398402 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Blocking the pathway with cyclopamine or anti-SHH antibodies inhibits the proliferation of GLI1+/PSA+ primary prostate tumor cultures.
|
15314219 |
2004 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population?
|
17257635 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy.
|
15936010 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Differential regulation of clusterin and its isoforms by androgens in prostate cells.
|
17148459 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we have applied RNA in situ hybridization and immunohistochemistry assays to measure the expressions of SRRM4, NEPC markers (SYP, CD56, and CHGA), and adenocarcinoma (AdPC) markers (AR, PSA) in a series of tissue microarrays constructed from castrate-resistant prostate tumors, treatment-naïve tumors collected from radical prostatectomy, and tumors treated with neoadjuvant hormonal therapy (NHT) for 0-12 months.
|
30155992 |
2019 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.
|
17003774 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
|
12210484 |
2002 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Transrectal ultrasound and prostate-specific antigen in prostate cancer.
|
19032406 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of mRNA and protein of AR as well as its target gene prostate-specific antigen (PSA) was much higher in metastatic prostate tumors than in primary prostate tumors.
|
30142696 |
2018 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.
|
16581345 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability.
|
18645024 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results suggest that overexpression of CRISP-3 in prostate tumor may maintain higher PSA expression and lower ANXA1 expression.
|
26369530 |
2016 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation.
|
16934957 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
|
12949939 |
2003 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings demonstrate the therapeutic benefits of simvastatin for prostate cancer and suggest a link between simvastatin, regulation of Akt activity, and PSA expression in prostate tumors.
|
21059805 |
2011 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells.
|
15014041 |
2004 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Endocrine approaches in the therapy of prostate carcinoma.
|
15790600 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.
|
27318894 |
2016 |